|
Hepsera
(Adefovir Dipivoxil)
Articles on Hepsera
Prescribing
Information
What are Hepsera's
Possible Side Effects?
Important Safety Information
about Hepsera
Is There Resistance
to Hepsera?

Articles on Hepsera (Adefovir Dipivoxil)
Tenofovir
(Viread) Effective for Treatment of Chronic Hepatitis B
Patients with Suboptimal Response to Adefovir
(Hepsera)
5-7-2010
Entecavir (Baraclude) Works
Well in Patients with Adefovir-resistant
Hepatitis B, but Lamivudine Resistance Compromises Efficacy
4/02/2010
Adding
Adefovir (Hepsera)
to Lamivudine (Epivir-HBV) Extends Biochemical Response,
But May Cause Kidney Problems
3/19/2010
Efficacy
and Safety of Entecavir Versus
Adefovir in Chronic Hepatitis B Patients with
Evidence of Hepatic Decompensation
11/03/09
Tenofovir
Disoproxil Fumarate for patients with chronic hepatitis
B who have previously failed Lamivudine
and
Adefovir: effects of baseline sequence mutations
on virological response.
11/03/09
Entecavir
(Baraclude) Demonstrates Greater Antiviral Activity than
Adefovir (Hepsera) in
Hepatitis B Patients with Decompensated Liver Disease
11/03/09
Entecavir (ETV) Therapy in Chronic Hepatitis
B Patients Previously Treated with Adefovir
(ADV) with Incomplete Response On-Treatment or
Relapse Off-Treatment
6/05/09
Half
of HBeAg Negative Chronic Hepatitis B Patients Maintain
Response up to 5 Years after Stopping Long-term Adefovir (Hepsera)
5/05/09
Chronic
Hepatitis B Patients Who Had Incomplete Response or Relapse
on Adefovir (Hepsera)
Respond Well to Entecavir (Baraclude)
5/01/09
Some
Individuals Harbor HBV with Adefovir (Hepsera) and Tenofovir
(Viread) Resistance Mutations before They Ever Receive Treatment
4/17/09
Two Year Tenofovir Disoproxil Fumarate (TDF) Treatment
and Adefovir Dipivoxil (ADV)
Switch Data in HBeAg-Positive Patients With Chronic Hepatitis
B (Study 103)
3/27/09
Adefovir
(Hepsera) Prevents Post-transplant HBV Recurrence
as well as HBIG
1/27/2009
Higher
Dose of Adefovir (Hepsera)
Are Not Effective for Chronic Hepatitis B Patients with
Lamivudine (Epivir) Resistance
1/09/2009

What
are Hepsera's Possible Side Effects?
Hepsera®
(adefovir dipivoxil) was compared to a sugar pill (placebo)
in clinical trials. The most common side effects observed
were weakness, headache, stomach pain and nausea.
Hepsera
also can cause the following serious side effects (See Important
Safety Information): very serious hepatitis if you stop
taking it, a severe kidney problem called nephrotoxicity,
lactic acidosis (buildup of acid in the blood) and liver
problems.
The
most common side effects in patients with liver transplants
and chronic hepatitis B were weakness, headache, stomach
pain and itching. Some patients with liver transplants also
had changes in the way their kidneys worked. If you notice
any side effects while taking Hepsera, talk to your healthcare
provider about what to do.
Important
Safety Information
1. Some people who stop taking Hepsera get a very
serious hepatitis. This usually happens within 12 weeks
after stopping. You will need to have regular blood tests
to check for liver function and hepatitis B virus levels
if you stop taking Hepsera.
2.
Hepsera may cause a severe kidney problem called nephrotoxicity.
It usually happens in people that already have a kidney
problem, but it can happen to anyone that uses Hepsera.
You will need to have regular blood tests to check for kidney
function while you are taking Hepsera.
3.
Some people who have taken medicines like Hepsera that
are called nucleoside or nucleotide analogs have developed
a serious condition called lactic acidosis (build up of
an acid in the blood). Lactic acidosis is a medical
emergency and must be treated in the hospital. Call your
doctor right away if you get any of the following signs
of lactic acidosis:
You
feel very weak or tired.
You have unusual (not normal) muscle pain.
You have trouble breathing.
You have stomach pain with nausea and vomiting.
You feel cold, especially in your arms and legs.
You feel dizzy or lightheaded.
You have a fast or irregular heartbeat.
Some
people who have taken medicines like Hepsera have developed
serious liver problems called hepatotoxicity, with liver
enlargement (hepatomegaly) and fat in the liver (steatosis).
Call your doctor right away if you get any of the following
signs of liver problems.
Your
skin or the white part of your eyes turns yellow (jaundice).
Your urine turns dark.
Your bowel movements (stools) turn light in color.
You don't feel like eating food for several days or longer.
You feel sick to your stomach (nausea).
You have lower stomach pain.
You
may be more likely to get lactic acidosis or serious liver
problems if you are very overweight (obese) or have been
taking nucleoside analog medicines [Atripla (efavirenz
plus emtricitabine plus tenofovir disoproxil fumarate),
Combivir® (zidovudine plus lamivudine), Emtriva®
(emtricitabine), Epivir® Epivir-HBV® (lamivudine),
Epzicom (abacavir plus lamivudine), Hivid® (zalcitabine),
Retrovir® (zidovudine), Trizivir® (zidovudine
plus lamivudine plus abacavir), Truvada® (emtricitabine
plus tenofovir disoproxil), Videx® (didanosine), Viread®
(tenofovir disoproxil fumarate), Zerit® (stavudine)
and Ziagen® (abacavir)] for a long time.
4.
If you get or have HIV that isn't being treated with
medicines, Hepsera may increase the chances your HIV infection
cannot be helped with usual HIV medicines. This can
happen if you get or have HIV and don't know it, or if
your HIV is not being treated while you are taking Hepsera.
You should get an HIV test before you start taking Hepsera
and any time after that when there's a chance you were
exposed to HIV.
Is
There Resistance to Hepsera?
Drug resistance is a primary concern of infectious disease
specialists around the world. Any virus can develop drug
resistance, and may even develop resistance to more than
one drug. Resistance occurs when viruses acquire ways
to survive the effects of the drugs that were designed
to weaken them. Resistance to antiviral drugs presents
an obstacle to providing effective long-term treatment
of viral diseases, such as chronic hepatitis B.
Hepsera®
was studied in clinical trials to find out whether or
not resistance would develop. Through 144 weeks (about
3 years), resistance mutations were identified that may
reduce the effectiveness of Hepsera. After 3 years of
continuous treatment, 4/100 patients developed resistance
to Hepsera in clinical trials.
In
clinical trials, Hepsera was found to work well in people
who had hepatitis B virus that was resistant to the currently
approved chronic hepatitis B treatment, lamivudine.
|